A study to compare the effects of ketofol, ketamine and etomidate anaesthesia on neuro psychological outcomes in patients with major depressive disorder

The effects of ketofol , ketamine and etomidate anesthesia for modified ECT on neuropsychological outcome in major depressive disorder patients: A randomized comparative study - NIL

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/05/087135

Enrollment

Registered

2025-05-20

Start date

Unknown

Completion date

Unknown

Last updated

2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F339- Major depressive disorder, recurrent, unspecified

Interventions

Intervention1: Three anesthetic agents are being studied.Ketofol (ketamine + propofol), Ketamine, and Etomidate administered during ECT.: Since this is a randomized, comparative study, each of these t

Eligibility

Inclusion criteria

Inclusion criteria: diagnosed with major depressive disorder (as per DSM-5 criteria) Treatment resistant depression with clinical indication of ECT

Exclusion criteria

Exclusion criteria: Patients with any comorbid psychiatric disorders (except tobacco use disorder). Patients with pre-existing cognitive impairment because of any cause will be excluded to ensure baseline cognitive homogeneity. Patients with medical conditions contraindicating the use of ketofol, ketamine or etomidate Pregnancy and lactation Allergy or hypersensitivity to ketofol, ketamine, etomidate Patient refusal

Design outcomes

Primary

Measure	Time frame
to compare the effects of ketofol, ketamine, and etomidate anesthesia on neuropsychological outcomes in major depressive disorder patients undergoing ECT. Cognitive and depression severity assessments, using MOCA and PHQ-9, are conducted at baseline, after week one, and post-final ECT sessions for evaluationTimepoint: baseline evaluation night before first ECT, second evaluation one week after , third after completion of all ECT sessions	—

Measure

Time frame

to compare the effects of ketofol, ketamine, and etomidate anesthesia on neuropsychological outcomes in major depressive disorder patients undergoing ECT. Cognitive and depression severity assessments, using MOCA and PHQ-9, are conducted at baseline, after week one, and post-final ECT sessions for evaluationTimepoint: baseline evaluation night before first ECT, second evaluation one week after , third after completion of all ECT sessions

—

Secondary

Measure	Time frame
- seizure duration, hemodynamic profile, & post convulsion complications, including sialorrhea, myalgia, nausea, & agitation Timepoint: in each ECT session	—

Countries

India

Contacts

Public ContactArushi Jaiswal

King George Medical University , Lucknow

dr.vinitasingh70@gmail.com9415080782

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026